Ordering Recommendation

Useful as a supplemental assay for repeatedly reactive third- or fourth-generation HIV screen tests when following the CDC's recommended HIV testing algorithm. This test should not be used as a rapid screen or as a follow-up test for a positive rapid screen.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation
Collect

Lavender (EDTA), or pink (K2EDTA).

Specimen Preparation

Separate from cells within 24 hours of collection. Transfer 3 mL plasma into an ARUP standard transport tube dedicated only for HIV testing. (Min: 1 mL) Remove particulate material.

Storage/Transport Temperature

Frozen.

Unacceptable Conditions

Serum. Heparinized or citrated plasma specimens. Specimens submitted in plasma preparation tube. Specimens containing particulate material. Severely hemolyzed or heat-inactivated specimens.

Remarks
Stability

After separation from cells: Ambient: 24 hours (CRITICAL: SHIP FROZEN); Refrigerated:72 hours; Frozen: 3 months (avoid repeated freeze/thaw cycles)

Methodology

Qualitative Immunoassay/Quantitative Transcription-Mediated Amplification (TMA)

Performed

Varies

Reported

1-2 days

Reference Interval

Effective November 12, 2018

Test Number
Components
Reference Interval
HIV-1 Antibody Negative
HIV-2 Antibody Negative
3000867 Human Immunodeficiency Virus 1 (HIV-1) by Quantitative NAAT, Plasma Not detected

Interpretive Data

This test should not be used for blood donor screening, associated reentry protocols, or for screening human cells, tissues, and cellular- and tissue-based products (HCT/P).

Compliance Category

FDA

Note

For use only when patient has a repeatedly reactive third- or fourth-generation HIV screen test result. This test discriminates between HIV-1 and HIV-2 antibodies. Results for each type are reported. This test is for use as the antibody differentiation test in the specific multitest algorithm. It is not to be ordered as a rapid screen test and cannot be used as a supplemental test if the initial screen test was a rapid test.

If the HIV-1/ 2 antibody differentiation immunoassay is Negative or Indeterminate, then the Human Immunodeficiency Virus 1 (HIV-1) by Quantitative NAAT, Plasma, will be added. Additional charges apply. Refer to Human Immunodeficiency Virus 1 (HIV-1) by Quantitative NAAT, Plasma (ARUP test code 3000867) for additional information regarding Performed or Reported times, Interpretive Data, and Notes for the reflex test.

The multitest algorithm is recommended by the Centers for Disease Control and Prevention (CDC) and the Clinical Laboratory Standards Institute (CLSI) for the diagnosis of HIV (refer to https://arupconsult.com/content/human-immunodeficiency-virus).

Hotline History

N/A

CPT Codes

86701; 86702; if reflexed, add 87536

Components

Component Test Code* Component Chart Name LOINC
2012670 HIV-1/2 Ab Differentiation Immunoassay 77202-0
2012671 HIV-1 Antibody 68961-2
2012672 HIV-2 Antibody 81641-3
2012673 HIV Serologic Interpretation 80203-3
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • Geenius
  • HIV Diagnosis
  • HIV Multispot
  • HIV-1 & 2 Antibody Differentiation
  • HIV-1 and HIV-2 Antibody Differentiation
  • HIV-1 Antibody by Multispot
  • Human Immunodeficiency Virus 1/2 (HIV-1/2) Antibody, Differentiation With Reflex to HIV-1 RNA
Human Immunodeficiency Virus Types 1 and 2 (HIV-1/2) Antibody Differentiation, Supplemental, with Reflex to HIV-1 Quantitative NAAT, Plasma